The trademark application EMRUXIV was filed by Principia Biopharma Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on November 16, 2022, and it was registered by office on February 23, 2023 without any oppositions.
The application was filed in English (French was selected as the second language).